2008-09-02 23:46:01 -
- CHAD Therapeutics, Inc. (OTCBB:CHAD) announced today that its common stock has begun trading on the OTC Bulletin Board system under the new symbol CHAD.
On July 29, 2008, CHAD announced that its Dormio Tech division received 510(K) clearance from the FDA to market the Company's proprietary FloCHANNEL(R) Diagnostic System, Dormio's first product for the large and rapidly growing
sleep disorder market. CHAD currently expects to begin shipping this new device and associated disposables by September.
About CHAD Therapeutics
CHAD Therapeutics, Inc. develops and markets innovative products for the sleep disorder market. For more information, visit www.dormiotech.com.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.
The foregoing statements regarding prospects for future earnings and revenues, future sales trends and the introduction of products under development are forward-looking statements that involve certain risks and uncertainties. A number of important factors could cause actual results to differ materially from those contemplated by such forward-looking statements. These include the introduction of new products with perceived competitive advantages over the Company's products, changes or proposed changes in health care reimbursement which affect home care providers, and DORMIO's ability to anticipate and respond to technological and economic changes in the sleep market. Moreover, the success of the Company's products and products under development will depend on their efficacy, reliability and the health care community's perception of the products' capabilities and benefits, the degree of acceptance the products achieve among sleep labs and patients, and, with respect to products under development, obtaining timely regulatory approval. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Company's annual and quarterly reports filed with the Securities and Exchange Commission under the caption "Outlook: Issues and Risks."
Company Contact:
CHAD Therapeutics, Inc.
Earl L. Yager, President and CEO, 818-882-0883
Fax: 818-882-1809
www.DormioTech.com
or
Investor Contact:
Neil Berkman Associates
310-826-5051
info@BerkmanAssociates.com 
